Altre lingue Candel Therapeutics, Inc.

Azioni

CADL

US1374041093

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
6,05 ^USD	+2,37%		+11,21%	+311,56%

11/04	Aggiornamento settoriale: i titoli del settore sanitario calano giovedì pomeriggio	MT
11/04	Le azioni di Candel Therapeutics aumentano dopo la designazione di farmaco orfano da parte della FDA per un potenziale farmaco contro il cancro al pancreas	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	16/04
Sector Update: Health Care Stocks Decline Thursday Afternoon	11/04
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	11/04
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation	11/04
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer	11/04
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	05/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	05/04
Top Premarket Gainers	05/04
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial	05/04
Top Midday Gainers	04/04
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights	28/03
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K	28/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Candel Therapeutics, Inc.

Azioni

CADL

US1374041093

Altre lingue

Filtri